Gene-Edited cells take on lupus and scleroderma in first human test
NCT ID NCT06925542
First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activity by targeting and calming the overactive immune system. Because it's a Phase 1 study, the main focus is safety, not yet proving the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGSt Louis, Missouri, 63130, United States
-
Research Site 10
RECRUITINGCórdoba, 14004, Spain
-
Research Site 11
RECRUITINGSeville, 41013, Spain
-
Research Site 12
RECRUITINGMainz, 55131, Germany
-
Research Site 13
RECRUITINGCologne, 50937, Germany
-
Research Site 14
RECRUITINGNew Orleans, Louisiana, 70118, United States
-
Research Site 2
RECRUITINGChicago, Illinois, 63110, United States
-
Research Site 3
RECRUITINGHanover, 30625, Germany
-
Research Site 4
RECRUITINGRedwood City, California, 94063, United States
-
Research Site 5
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Research Site 6
RECRUITINGBoston, Massachusetts, 02118, United States
-
Research Site 7
RECRUITINGAugsburg, 86156, Germany
-
Research Site 8
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site 9
RECRUITINGPamplona, 31008, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CRISPR-edited immune cells (CTX112) from a healthy donor
What this could lead to
If it works, this could point toward a one-time treatment that resets the immune system for people with severe autoimmune diseases like lupus.
What could go wrong
This is a very early Phase 1 trial with only 80 people, so safety and effectiveness are not yet proven. There are risks from the cell infusion and possible long-term immune suppression.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.